Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01002248 · ClinicalTrials.gov registry record · Phase 3
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase 3 study, sponsored by AEterna Zentaris.
- Terminated
- Registry status
- Phase 3
- Development phase
- 135
- Enrollment target
NCT01002248 is a Phase 3 study that was terminated before completion, run by AEterna Zentaris. The registered enrollment target is 135 participants.
The verdict
NCT01002248, a Phase 3 study, was terminated before completion, sponsored by AEterna Zentaris.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 135 participants
- Enrollment target
Study Summary
This is a randomized Phase III study to evaluate the efficacy and safety of perifosine when added to the combination of bortezomib and dexamethasone in multiple myeloma patients who have relapsed on a prior bortezomib treatment regimen.
Interventions
- DRUG Dexamethasone
- DRUG Bortezomib
- DRUG Perifosine
- DRUG Perifosine Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2009-12 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01002248
The ClinicalTrials.gov registry entry for NCT01002248 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AEterna Zentaris, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dexamethasone is the first listed.
NCT01002248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01002248 about?
NCT01002248 is a clinical study titled "Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients". This is a randomized Phase III study to evaluate the efficacy and safety of perifosine when added to the combination of bortezomib and dexamethasone in multiple myeloma patients who have relapsed on a prior bortezomib treatment regimen.
What is the current status of trial NCT01002248?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 135 participants. The study started on 2009-12. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01002248?
The interventions under investigation include: Dexamethasone (DRUG), Bortezomib (DRUG), Perifosine (DRUG), Perifosine Placebo (DRUG).
Who is sponsoring clinical trial NCT01002248?
This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.